

[IUSM Newsroom](#) »

 [PRINT](#)  [SHARE](#)

 [Print Quality Photo](#)

Media Contacts

Michael Schug

 [Indianapolis](#)
 [Office 317-278-0953](#)
 maschug@iupui.edu

IU Simon Cancer Center seeks high school, college applicants for 2015 Summer Research Program

Dec. 10, 2014

INDIANAPOLIS -- Students interested in gaining hands-on experiences in cancer research are encouraged to apply for the 2015 Summer Research Program at the Indiana University Melvin and Bren Simon Cancer Center.

The annual Summer Research Program, held in partnership with the Indiana University-Purdue University Indianapolis [Center for Research and Learning](#), places students with a mentor physician or researcher for nine weeks, June 1 to July 24. Students work with faculty who are conducting studies in the most progressive areas of cancer research.

The program's primary goal is to increase the number of underrepresented populations engaged in basic, clinical, and prevention and control cancer research by providing positive and meaningful first-hand exposure to those fields.

Each student receives a stipend of \$3,200. Students are responsible for their own housing and transportation arrangements.

The Summer Research Program provides students an opportunity to:

- Interact with any of the cancer center's [research programs](#), [shared facilities](#) and more than 100 [world-renowned investigators](#).
- Gain exposure to a wide range of basic science, translational and clinical research activities.
- Continually interact with and learn from other students, clinical and postdoctoral fellows, and faculty.
- Attend weekly career development workshops related to gaining admission to graduate and professional programs of study.

Students are selected based on interest in biomedical or behavioral science, academic performance and personal interviews. High school students who participate must have completed at least their junior year and have maintained a grade-point average of at least 3.0 on a 4.0 scale. Undergraduates in the program must have completed 24 hours of college credit, be majoring in a biomedical or behavioral science, and have maintained a grade-point average of at least 3.2.

Additional information and an online application are available at www.cancer.iu.edu/srp. For more information, contact the IUPUI Center for Research and Learning at crlstaff@iupui.edu.

The application deadline is Feb. 27. Those students selected as finalists will be invited to campus for an interview in April.

###

About the Center for Research and Learning

The Center for Research and Learning is associated with the Office of the Vice Chancellor for Research. The center is dedicated to serving students through a series of undergraduate research programs overseen by center program leaders. These programs offer students the opportunity to carry out innovative research, scholarship and creative activity with faculty mentors through internally and externally funded programs.



INDIANA UNIVERSITY

IU SIMON CANCER CENTER

Indiana University Melvin and Bren Simon Cancer Center



IUSCC news

January 2015

News briefs

Dr. Masterson is data and safety monitoring committee chair



Masterson

Tim Masterson, MD, has been named chair of the Data and Safety Monitoring Committee. In this role, he will review all clinical trials conducted at the IU Simon Cancer Center for progress and safety, review all adverse events requiring expedited reporting as defined in the protocol, and review reports generated by the cancer center data quality control review process.

Dr. Masterson is an assistant professor of urology at the IU School of Medicine. His research interest, in which he works collaboratively with researchers at Purdue, includes exploration of novel tumor markers, molecular imaging for screening and staging prostate cancer, and novel compounds for nerve regeneration.

He earned his medical degree from IU School of Medicine, and he completed his residency at the University of Utah Health Science Center, and his fellowship at Memorial Sloan-Kettering Cancer Center.

He succeeds David Delgado who has been named director of BMT at Riley.

"David deserves a special call-out for his efforts in this role and his help during our recent competing renewal, especially amid all of his other responsibilities," **Pat Loehrer, MD**, IU Simon Cancer Center director, said.

IUSM named to top residency training rankings

Four of the residency training programs at Indiana University School of Medicine have been recognized for excellence in the first regional residency program rankings by Doximity. The IU residency programs ranked in the top 10 in the Midwest are anesthesiology, diagnostic radiology, pediatrics and urology.

[full story>](#)





Pat Loehrer, MD, cuts the ribbon to the new Hoosier Cancer Research Network (HCRN) board room named in his honor. Dr. Loehrer is a co-founder of HCRN, formerly Hoosier Oncology Group (HOG). The HCRN recently hosted an open house at its new location, 500 N. Meridian St.

Cancer clinical program earns accreditation

The cancer center's clinical program, operated by IU Health, again has earned full accreditation status from the [Commission on Cancer of the American College of Surgeons](#). To earn voluntary accreditation, a cancer program must meet 34 quality-care standards, be evaluated every three years through a survey process, and maintain levels of excellence in the delivery of comprehensive, patient-centered care. The next accreditation survey will be in 2017.

What services does the CTO provide?

The [Clinical Trials Office](#) (CTO) has produced a catalog of its services for cancer center members. The CTO provides:

- Protocol Management
- Regulatory Support
- Data Systems
- Budgeting/Contracting
- Education/Training
- Quality Assurance and Monitoring
- Multicenter Clinical Research Coordination

View the online [catalog](#).

Society for Immunotherapy of Cancer is accepting applications for 2015 postdoc fellowship

The Society for Immunotherapy of Cancer has announced that it is accepting applications for the 2015 postdoctoral fellowship in cancer immunotherapy in partnership with Merck.

The SITC-Merck Cancer Immunotherapy Clinical Fellowship Award will provide funding support in the amount of \$100,000 for one year of salary, equipment, supplies and fringe benefit support to a young investigator. The award also includes travel support to attend an upcoming SITC Annual Meeting and the opportunity to present their work to the cancer immunotherapy community at this

venue.

Applications will be accepted Monday, Jan. 26 until Monday, March 9. Visit [SITC](#) for complete details.

Reminder

Cincinnati Cancer Institute hosts survivorship program in March 2015 The University of Cincinnati Cancer Institute's Cancer Survivorship Program is hosting "Transforming Cancer Survivorship Through Research and Best Practice," from 8 a.m. to 4 p.m., Friday, March 27, at the Kingsgate Marriott Conference Center, 151 Goodman Drive, Cincinnati.

The event is planned to educate and meet the needs of physicians, nurses, psychologists, residents, medical students, social workers, counselors, dieticians and other oncology health professionals on the best practices and latest research for cancer survivorship. Julia Rowland, PhD, director of the National Cancer Institute Office of Cancer Survivorship, will be the keynote speaker.

For the full agenda, abstract requirements or to register, visit www.uchealth.com/events/transformingsurvivorship. Questions? Contact Shanah Cole at (513) 558-9908.

Cancer center members in the news

- **Lindsey Mayo**, PhD and colleagues wrote "Src phosphorylation converts Mdm2 from a ubiquitinating to a neddylation E3 ligase," which was published in the [Proceedings of the National Academy of Sciences](#).



- **Elliot Andropy**, MD, is among 16 Indiana scientists who received a 2014 Collaboration in Translational Research award from the Indiana Clinical and Translational Sciences Institute. He and his collaborator -- V. Jo Davison of Purdue -- will receive support for early-stage research projects with the potential to attract additional support from outside federal and commercial agencies, including the National Institutes of Health and National Science Foundation.

- **Mircea Ivan**, MD, PhD; **Mark Kelley**, PhD; **Melissa Fishel**, PhD; and colleagues concluded that the activation of nuclear factor-erythroid-

related factor 2 is a potential mechanism of resistance to therapies based on redox factor-1 inhibition. They wrote "Apurinic/Apyrimidinic Endonuclease/Redox Factor-1 (APE1/Ref-1) Redox Function Negatively Regulates NRF2," which was published in [The Journal of Biological Chemistry](#).

New members

[Lata Balakrishnan](#), PhD
Department of Biology
Associate member, [EDT](#)

[Heiko Konig](#), MD, PhD
Department of Medicine
Associate member, [HMI](#)

[Natascia Marino](#), PhD

Department of Medicine
Associate member, [Breast Cancer](#)

[Uma Sankar](#), PhD
Department of Anatomy and Cell Biology
Full member, [TMM](#)

[Amikar Sehdev](#), MD, MPH
Department of Medicine
Associate member, [CPC](#)

Helpful Links

[Member Directory](#) | [Shared Facilities](#) | [Funding Opportunities](#) | [Research Programs](#)